Company intelligence / Profile preview

Mullan Pharmaceutical

Sarasota, Florida, United States

Ownership: Private
Development stage: Other

Overview

Mullan Pharmaceuticals is a biotechnology company focused on the development of therapeutic solutions for neurodegenerative disorders, particularly Alzheimer's disease. The company was founded by Dr. Mike Mullan and Dr. Fiona Crawford, who are well-known for their work at the Roskamp Institute and their discovery of the 'Swedish Mutation' in Alzheimer's research. The company's primary focus has been the repositioning of nilvadipine, a calcium channel blocker, as a treatment to reduce amyloid-beta levels in the brain. Mullan Pharmaceuticals operates in close alignment with the Roskamp Institute to translate basic research into clinical applications.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Roskamp InstituteArcher Pharmaceuticals

Beyond the preview

Go deeper on Mullan Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mullan Pharmaceutical.

Explore the full profile